AAIPharma expands in St. Louis, invests $10.7 million (MO)

ST. LOUIS — AAIPharma Services Corp./Cambridge Major Laboratories, a leading provider of custom manufacturing and development services for the pharmaceutical and biotechnology industries, announced the planned investment of at least $10.7 Million to relocate its St. Louis analytical testing facility to the Cortex Innovation Center.

AAI/CML provides innovative analytical testing solutions for manufacturers’ new drug entities, generic drugs, animal health products, medicated consumer health products, chemicals and biopharmaceuticals. Its analytical testing business is comprised of three centers of excellence in St. Louis; Wilmington, North Carolina; and Edison, New Jersey, to serve its regional, national and global customers.

Its current St. Louis facility employs approximately 80 full-time staff and specializes in chemical and microbiological analytical testing including raw material testing, drug product release, stability, and environmental monitoring for both sterile and non-sterile drugs.

The new facility is a response to increased customer demand and the growing trend of analytical testing outsourcing within the pharmaceutical and biotechnology industries. It will house state-of-the-art equipment in addition to its existing service offerings, and will provide new testing capabilities to meet industry and changing regulatory requirements, such as glass and plastic containers testing for pharmaceutical use, elemental impurities, disinfectant qualification and efficacy studies.

Visit the company’s Careers page here.

Source: AAIPharma

Shared By